|drug2916||SARS-CoV-2 convalescent plasma Wiki||0.50|
|drug3199||Standard of care Wiki||0.19|
There is one clinical trial.
A total of 25 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2. The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.
Description: Percentage of all subjects vaccinated with IPV with antibodies to SARS-CoV-2 RdRpMeasure: Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination Time: Day 28
Description: Antibodies raised following IPV vaccination will be evaluated for neutralizing titer to both polio virus and SARS-CoV-2Measure: Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine Time: Day 28
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports